Strides Pharma Science Ltd (STAR) — Announcement | 11 September 2026
Strides Pharma Science announced that the USFDA completed a cGMP inspection at its Alathur formulations facility from September 2 to 11, 2026, issuing a Form 483 with three observations; the company will address them within the required timeframe and will update exchanges on any further developments.
About Strides Pharma Science Ltd (STAR)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when STAR files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track STAR — Free💡 Ask AI about this filing
📊 More STAR filings
- Announcement — 24 September 2026Strides Pharma Science Limited has announced that its trading window will close on October 1, 2026, ...
- 🟡 Sustainability Report — 23 September 2026Strides Pharma Science Limited released its FY26 Sustainability Report, detailing ESG performance ac...
- Announcement — 19 August 2026Strides Pharma Science announced that its Bengaluru flagship manufacturing facility received a USFDA...
- 🟡 Board Meeting — 18 August 2026Strides Pharma Science Limited held its 35th Annual General Meeting on August 14, 2026 via video con...
- 🔴 Financial Results — 31 July 2026Strides Pharma reported Q1 FY27 revenue of **₹12,654 crores**, up 13% YoY, driven by 17% growth in E...
🔥 Also filed on 11 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when STAR files new disclosures
Track STAR filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track STAR — FreeFree account · 2 AI queries/day